ReShape Lifesciences 10-Q 8 Nov 13 2013 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 30, 2013	Oct. 31, 2013
Document Information [Line Items]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-13	'
Document Fiscal Year Focus	'2013	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'ETRM	'
Entity Registrant Name	'EnteroMedics Inc	'
Entity Central Index Key	'0001371217	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	60,695,410

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$21,142,028	$22,308,781
Restricted cash	200,000	200,000
Accounts receivable	53,282	52,406
Inventory	1,172,275	1,271,207
Prepaid expenses and other current assets	570,289	571,654
Total current assets	23,137,874	24,404,048
Property and equipment, net	632,467	609,672
Other assets	893,394	1,082,765
Total assets	24,663,735	26,096,485
Current liabilities:	'	'
Current portion of notes payable	4,000,000	3,000,000
Accounts payable	180,242	340,555
Accrued expenses	3,727,940	3,673,609
Accrued interest payable	526,498	523,678
Total current liabilities	8,434,680	7,537,842
Notes payable, less current portion (net discounts of $171,591 and $316,028 at September 30, 2013 and December 31, 2012, respectively)	3,828,409	6,683,972
Total liabilities	12,263,089	14,221,814
Commitments and contingencies (Note 4)	'	'
Stockholders' equity:	'	'
Common stock, $0.01 par value; 125,000,000 shares authorized; 58,618,270 and 41,843,270 shares issued and outstanding at September 30, 2013 and December 31, 2012, respectively	586,183	418,433
Additional paid-in capital	231,194,254	211,628,650
Deficit accumulated during development stage	-219,379,791	-200,172,412
Total stockholders' equity	12,400,646	11,874,671
Total liabilities and stockholders' equity	$24,663,735	$26,096,485

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Notes payable, less current portion, discounts	$171,591	$316,028
Common stock, par value	$0.01	$0.01
Common stock, shares authorized	125,000,000	125,000,000
Common stock, shares issued	58,618,270	41,843,270
Common stock, shares outstanding	58,618,270	41,843,270

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended		129 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Sales	'	'	'	$311,493	$311,493
Cost of goods sold	'	'	'	231,520	231,520
Gross profit	'	'	'	79,973	79,973
Operating expenses:	'	'	'	'	'
Research and development	2,762,478	2,580,653	8,207,211	7,521,177	135,656,829
Selling, general and administrative	3,207,943	2,991,817	10,153,495	8,347,481	70,283,358
Total operating expenses	5,970,421	5,572,470	18,360,706	15,868,658	205,940,187
Operating loss	-5,970,421	-5,572,470	-18,360,706	-15,788,685	-205,860,214
Other income (expense):	'	'	'	'	'
Interest income	1,184	3,193	4,767	7,353	4,050,907
Interest expense	-224,771	-263,713	-733,424	-636,607	-13,198,029
Change in value of warrant liability	'	'	'	'	-3,840,622
Other, net	-109,286	-13,850	-118,016	-15,447	-400,865
Net loss	($6,303,294)	($5,846,840)	($19,207,379)	($16,433,386)	($219,248,823)
Net loss per share - basic and diluted	($0.11)	($0.14)	($0.36)	($0.42)	'
Shares used to compute basic and diluted net loss per share	55,978,107	40,984,216	52,864,039	38,810,762	'

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Comprehensive Loss (USD $)	3 Months Ended		9 Months Ended		129 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Net loss	($6,303,294)	($5,846,840)	($19,207,379)	($16,433,386)	($219,248,823)
Change in unrealized gain (loss) on available for sale investments	'	-116	'	-692	'
Comprehensive loss	($6,303,294)	($5,846,956)	($19,207,379)	($16,434,078)	($219,248,823)

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended		129 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Cash flows from operating activities:	'	'	'
Net loss	($19,207,379)	($16,433,386)	($219,248,823)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'	'
Depreciation	124,418	177,587	2,611,446
Loss on sale of equipment	'	4,241	74,894
Stock-based compensation	4,376,955	2,739,319	23,065,443
Amortization of commitment fees, debt issuance costs and original issue discount	155,862	152,932	4,249,795
Amortization of short-term investment premium or discount	'	4,719	-300,071
Change in value of warrant liability	'	'	3,840,622
Other, net	8,030	'	8,030
Change in operating assets and liabilities:	'	'	'
Accounts receivable	-8,906	-52,649	-61,312
Inventory	98,932	-542,716	-1,172,275
Prepaid expenses and other current assets	1,365	246,380	-570,289
Other assets	177,946	-182,984	-872,450
Accounts payable	102,936	-271,228	179,514
Accrued expenses	54,331	-2,902,846	3,727,940
Accrued interest payable	2,820	66,230	692,320
Net cash used in operating activities	-14,112,690	-16,994,401	-183,775,216
Cash flows from investing activities:	'	'	'
Increase in restricted cash	'	'	-200,000
Purchases of short-term investments available for sale	'	'	-19,890,213
Maturities of short-term investments available for sale	'	1,000,000	19,854,414
Purchases of short-term investments held to maturity	'	'	-22,414,130
Maturities of short-term investments held to maturity	'	'	22,750,000
Purchases of property and equipment	-410,462	-51,803	-3,318,078
Net cash (used in) provided by investing activities	-410,462	948,197	-3,218,007
Cash flows from financing activities:	'	'	'
Proceeds from stock options exercised	'	'	215,684
Proceeds from warrants exercised	9,500	5,546,160	6,463,936
Proceeds from sale of common stock and warrants for purchase of common stock	16,634,310	5,050,000	136,038,749
Common stock financing costs	-1,287,411	-367,871	-11,133,712
Payment to shareholders for fractional shares upon reverse stock split	'	'	-355
Proceeds from sale of Series A, B and C convertible preferred stock	'	'	63,766,564
Series A, B and C convertible preferred stock financing costs	'	'	-1,658,662
Proceeds from notes payable and convertible notes payable	'	5,347,807	47,993,774
Repayments on notes payable	-2,000,000	-752,841	-33,178,928
Debt issuance costs	'	-50,000	-371,799
Net cash provided by financing activities	13,356,399	14,773,255	208,135,251
Net (decrease) increase in cash and cash equivalents	-1,166,753	-1,272,949	21,142,028
Cash and cash equivalents:	'	'	'
Beginning of period	22,308,781	28,487,688	'
End of period	21,142,028	27,214,739	21,142,028
Supplemental disclosure:	'	'	'
Interest paid	574,741	417,445	8,247,309
Noncash investing and financing activities:	'	'	'
Cancellation of Alpha Medical, Inc. Series A convertible preferred stock and common stock	'	'	-661,674
Issuance of Beta Medical, Inc. Series A convertible preferred stock in exchange for Alpha Medical, Inc. Series A convertible preferred stock and common stock	'	'	661,674
Value of warrants issued with debt and for debt commitment	'	237,349	4,070,532
Value of warrants issued with sale of common and preferred stock offerings	'	'	1,684,832
Cashless exercise of warrants	'	'	5,244,778
Conversion of notes and interest payable to Series B and C convertible preferred stock	'	'	6,980,668
Options issued for deferred compensation	'	'	10,898
Common stock issued to Mayo Foundation and for deferred compensation	'	'	1,770,904
Reclassification of warrant liability	'	'	2,932,766
Conversion of convertible preferred stock to common stock	'	'	$51,132

Summary_of_Significant_Account

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2013
Summary of Significant Accounting Policies	'
	(1) Summary of Significant Accounting Policies
	Description of Business
	EnteroMedics Inc. (formerly Beta Medical, Inc.) (the Company) is developing medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company was incorporated in the state of Minnesota on December 19, 2002 and was reincorporated in Delaware on July 22, 2004. The Company is in the development stage and since inception has devoted substantially all of its resources to recruiting personnel, developing its product technology, obtaining patents to protect its intellectual property and raising capital, and thus far has only derived revenues from its primary business activity in 2012. The Company is headquartered in St. Paul, Minnesota. In January 2006, the Company established EnteroMedics Europe Sárl, a wholly-owned subsidiary located in Switzerland.
	Since inception, the Company has incurred losses through September 30, 2013 totaling $219.2 million and has not generated positive cash flows from operations. The Company expects such losses to continue into the foreseeable future as it continues to develop and commercialize its technologies. The Company may need to obtain additional financing and there can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. If adequate funds are not available, the Company may have to delay development or commercialization of products or license to third parties the rights to commercialize products or technologies that the Company would otherwise seek to commercialize. See Note 2.
	Basis of Presentation
	The Company has prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. The Company’s fiscal year ends on December 31.
	The accompanying condensed consolidated financial statements and notes thereto are unaudited. In the opinion of the Company’s management, these statements include all adjustments, which are of a normal recurring nature, necessary to present a fair presentation. Interim results are not necessarily indicative of results for a full year. The condensed consolidated balance sheet as of December 31, 2012 was derived from audited consolidated financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The information included in this Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
	Principles of Consolidation
	The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.
	Fair Value of Financial Instruments
	Carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short maturities. The fair value of the Company’s long-term debt (including the current portion) is approximately $8.2 million as of September 30, 2013 based on the present value of estimated future cash flows using a discount rate commensurate with borrowing rates available to the Company. If measured at fair value in the condensed consolidated financial statements, long-term debt (including the current portion) would be classified as Level 2 in the fair value hierarchy.
	The Company’s assets that are measured at fair value on a recurring basis are classified within Level 1 or Level 2 of the fair value hierarchy. The Company does not hold any assets that are measured at fair value using Level 3 inputs. The types of instruments the Company invests in that are valued based on quoted market prices in active markets include U.S. treasury securities. Such instruments are classified by the Company within Level 1 of the fair value hierarchy. U.S. treasuries are valued using unadjusted quoted prices for identical assets in active markets that the Company can access.
	The types of instruments the Company invests in that are valued based on quoted prices in less active markets, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency include U.S. agency securities, commercial paper, U.S. corporate bonds and municipal obligations. Such instruments are classified by the Company within Level 2 of the fair value hierarchy. The Company values these types of assets using consensus pricing or a weighted average price, which is based on multiple pricing sources received from a variety of industry standard data providers (e.g. Bloomberg), security master files from large financial institutions, and other third-party sources. The multiple prices obtained are then used as inputs into a distribution-curve-based algorithm to determine the daily market price.
	The Company did not hold any short-term investments as of September 30, 2013 and December 31, 2012.
	Cash and Cash Equivalents
	The Company considers highly liquid investments generally with maturities of 90 days or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximates market value. The Company’s cash equivalents are primarily in money market funds and certificates of deposit. The Company deposits its cash and cash equivalents in high-quality credit institutions. Under terms of the Company’s note payable agreement (see Note 5), in the event of default, the lender has the right to enforce an account control agreement and restrict the Company’s access to their cash and investment accounts.
	Restricted Cash
	The Company had $200,000 in a cash collateral money market account as of September 30, 2013 and December 31, 2012. Pursuant to a lease agreement the Company entered into with Roseville Properties Management Company in July 2008, the Company was required to deliver to Roseville Properties an irrevocable, unconditional, standby letter of credit in the amount of $200,000 on the second anniversary of the commencement of lease payments. The irrevocable standby letter of credit was issued by Silicon Valley Bank, who required the Company to set up a restricted cash collateral money market account to fully secure the standby letter of credit. The fully secured standby letter of credit was maintained through October 1, 2013, per the terms of the lease agreement.
	Inventory
	The Company accounts for inventory at the lower of cost or market and records any long-term inventory as other assets in the condensed consolidated balance sheets.
	Income Taxes
	Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance for deferred income tax assets is recorded when it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The Company has provided a full valuation allowance against the gross deferred tax assets. The Company’s policy is to classify interest and penalties related to income taxes as income tax expense in the condensed consolidated statements of operations.
	Comprehensive Loss
	Comprehensive loss is defined as the change in equity of a company during a period from transactions and other events and circumstances excluding transactions resulting from investment owners and distributions to owners. There was no difference from reported net loss for the three and nine months ended September 30, 2013. The difference from reported net loss for the three and nine months ended September 30, 2012 related entirely to changes in unrealized gains (losses) on available for sale investments.
	Revenue Recognition
	The Company recognizes revenue when persuasive evidence of an arrangement exists, title or risk of loss has passed, the selling price is fixed or determinable and collection is reasonably assured. The Company sells products internationally through distributors and recognizes revenue upon sale to the distributor as these sales are considered to be final and no right of return or price protection exists. Terms of sales to international distributors are generally EXW, reflecting that goods are shipped “ex works,” in which risk of loss is assumed by the distributor at the shipping point. The Company does not provide for rights of return to customers on product sales and therefore does not record a provision for returns.
	Research and Development Expenses
	Research and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product development, clinical trial expenses, including supplies, devices, explants and revisions, regulatory expenses, payroll and other personnel expenses, materials and consulting costs.
	Derivative Instruments
	The Company accounts for outstanding warrants that are not indexed to the Company’s stock or warrants issued when the Company has insufficient authorized and unissued stock available to share settle the outstanding warrants as derivative instruments, which require that the warrants be classified as a liability and measured at fair value with changes in fair value recognized currently in earnings and recorded separately in the condensed consolidated statements of operations.
	Net Loss Per Share
	Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted-average common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. The Company’s potential dilutive shares, which include outstanding common stock options and warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.
	The following table sets forth the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2013 and 2012:
		Three months ended						Nine months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Numerator:
	Net loss	$	(6,303,294	)	$	(5,846,840	)	$	(19,207,379	)	$	(16,433,386	)
	Denominator for basic and diluted net loss per share:
	Weighted-average common shares outstanding		55,978,107			40,984,216			52,864,039			38,810,762
	Net loss per share—basic and diluted	$	(0.11	)	$	(0.14	)	$	(0.36	)	$	(0.42	)
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:
		September 30,
		2013			2012
	Stock options outstanding		11,622,700			7,879,730
	Warrants to purchase common stock		25,565,950			21,493,883
	Recently Issued Accounting Standards
	There have been no significant changes in recent accounting pronouncements during the nine months ended September 30, 2013 as compared to the recent accounting pronouncements described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

Liquidity_and_Managements_Plan

Liquidity and Management's Plans	9 Months Ended
	Sep. 30, 2013
Liquidity and Management's Plans	'
	(2) Liquidity and Management’s Plans
	The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. For the period from inception (December 19, 2002) through September 30, 2013 the Company experienced net losses of $219.2 million and cash used in operations of $183.8 million. As of September 30, 2013, the Company has not emerged from the development stage and had $21.3 million of cash, cash equivalents and restricted cash. Assuming the Company does not receive any additional funds, it estimates that it has sufficient funds to operate into 2014 (including scheduled or potentially accelerated debt obligations). In order to fund on-going operating cash requirements beyond that point or to further accelerate and execute its business plan, including commercialization of the Maestro Rechargeable System, the Company will need to raise additional funds.
	Since inception, the Company has financed its activities principally from the sale of equity securities, debt financing and interest earned on investments. While the Company has been successful in the past in obtaining the necessary capital to support its operations, and has similar future plans, there is no assurance that the Company will be able to obtain additional equity capital or other financing under commercially reasonable terms and conditions, or at all. Furthermore, if the Company issues equity or debt securities to raise additional funds, existing shareholders may experience dilution and the new equity or debt securities it issues may have rights, preferences and privileges senior to those of existing stockholders. In addition, if the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable rights to products or proprietary technologies, or grant licenses on terms that are not favorable. If the Company cannot execute its plan to raise funds on acceptable terms, the Company will not be able to continue as a going concern, develop or enhance products, obtain the required regulatory clearances or approvals, execute the Company’s business plan, take advantage of future opportunities, or respond to competitive pressure or unanticipated customer requirements. If the Company is unable to obtain additional financing or the U.S. Food and Drug Administration (FDA) does not approve the Maestro Rechargeable System for commercial use in the U.S., the Company may be required to reduce the scope of, delay, or eliminate some or all of, its planned research, development and commercialization activities, which could materially harm its business. Any of these events would adversely affect the Company’s ability to achieve the Company’s development and commercialization goals, which could have a material adverse effect on the Company’s business, results of operations and financial condition. The Company’s financial statements do not include any adjustments relating to the recoverability or classification of assets or the amounts of liabilities that might result from the outcome of these uncertainties.

Inventory

Inventory	9 Months Ended
	Sep. 30, 2013
Inventory	'
	(3) Inventory
	From inception, inventory related purchases had been used for research and development related activities and had accordingly been expensed as incurred. In December 2011, the Company began receiving Australian Register of Therapeutic Goods (ARTG) listings for components of the Maestro Rechargeable System from the Australian Therapeutic Goods Administration (TGA), with the final components being listed on the ARTG in January 2012. As a result, the Company determined certain assets were recoverable as inventory beginning in December 2011. The Company accounts for inventory at the lower of cost or market and records any long-term inventory as other assets in the condensed consolidated balance sheets. There was approximately $863,000 and $862,000 of long-term inventory, primarily consisting of raw materials, as of September 30, 2013 and December 31, 2012, respectively.
	Current inventory consists of the following as of:
		September 30,		December 31,
		2013		2012
	Raw materials	$	307,420	$	198,647
	Work-in-process		748,197		1,051,286
	Finished goods		116,658		21,274
	Inventory	$	1,172,275	$	1,271,207

Commitments_and_Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2013
Commitments and Contingencies	'
	(4) Commitments and Contingencies
	Operating Lease
	The Company rents its office, warehouse and laboratory facilities under an operating lease, which expires on September 30, 2015. Total rent expense recognized for each of the three and nine months ended September 30, 2013 and 2012 was $67,718 and $203,154, respectively. At September 30, 2013, future minimum payments under the lease are as follows:
	Years ending December 31:
	Remaining three months in 2013	$	72,480
	2014		291,369
	2015		221,789
		$	585,638
	The Company is exposed to product liability claims that are inherent in the testing, production, marketing and sale of medical devices. Management believes any losses that may occur from these matters are adequately covered by insurance, and the ultimate outcome of these matters will not have a material effect on the Company’s financial position or results of operations. The Company is not currently a party to any litigation and is not aware of any pending or threatened litigation that could have a material adverse effect on the Company’s business, operating results or financial condition.
	The Company is evaluating its product, the Maestro System, in human clinical trials, including the EMPOWER trial and ReCharge trial. Both of these clinical trials require patients to be followed out to 60 months. The Company is required to pay for patient follow up visits only to the extent they occur. In the event a patient does not attend a follow up visit, the Company has no financial obligation. The Company is also required to pay for explants or revisions, including potential conversions of ReCharge control devices to active devices, should a patient request or be required to have one during the course of the clinical trials. The Company has no financial obligation unless an explant, revision or conversion is requested or required. Clinical trial costs are expensed as incurred.

Notes_Payable

Notes Payable	9 Months Ended
	Sep. 30, 2013
Notes Payable	'
	(5) Notes Payable
	On April 16, 2012, the Company entered into a Loan and Security Agreement (the Loan Agreement) with Silicon Valley Bank (SVB) pursuant to which SVB agreed to make term loans in an aggregate principal amount of up to $20.0 million ($10.0 million of which is not available as the Company did not meet the predefined primary efficacy measures of the ReCharge trial and did not meet certain financial objectives for 2012), on the terms and conditions set forth in the Loan Agreement.
	Pursuant to the Loan Agreement, a term loan was funded in the aggregate principal amount of $10.0 million on April 23, 2012. The term loan required interest only payments monthly through March 31, 2013 followed by 30 equal payments of principal in the amount of $333,333 plus accrued interest beginning on April 1, 2013 and ending on September 1, 2015, payable monthly. Amounts borrowed under the Loan Agreement bear interest at a fixed annual rate equal to 8.0%. A 5.0% final payment fee will be due on September 1, 2015. The Company may voluntarily prepay the term loan in full, but not in part, and any voluntary or mandatory prepayment is subject to applicable prepayment premiums and will also include the final payment fee. The Company was required to comply with certain financial covenants that required the Company to generate certain minimum amounts of revenue from the sale of its Maestro System and to implant certain minimum numbers of Maestro Systems during cumulative quarterly measurement periods beginning with the period ended March 31, 2013 and ending with the period ending June 30, 2015. The Company did not meet the financial covenants for the period ended March 31, 2013 and therefore entered into a First Amendment (the First Amendment) to the Loan Agreement on May 9, 2013 pursuant to which the Company and SVB agreed to new financial covenants.
	The First Amendment eliminated the financial covenants that required the Company to generate certain minimum amounts of revenue from the sale of its Maestro System and to implant certain minimum numbers of Maestro Systems during cumulative quarterly measurement periods beginning with the period ended March 31, 2013 and ending with the period ending June 30, 2015. It also removed SVB’s ability to require the Company to maintain a restricted cash balance of $7.5 million in an SVB account as a result of the Company not meeting the predefined primary efficacy measures of the ReCharge trial.
	The First Amendment added two new financial covenants, one of which requires the Company to receive cumulative aggregate net proceeds of at least $5.0 million by November 15, 2013, which has been fulfilled through the use of the equity distribution agreement with Canaccord Genuity Inc. (see Note 7), and $10.0 million by April 15, 2014 from new capital transactions. The amount required will adjust up or down based on the Company’s actual cash position compared to its financial plan. The second financial covenant requires the Company to maintain a liquidity ratio (unrestricted cash divided by outstanding debt) of at least 1.25:1.00 until it receives FDA approval for the Maestro Rechargeable System at which point it will be reduced to 0.75:1.00. The First Amendment does not change the interest rate or the amortization structure. The Company will pay SVB a $187,000 success fee in the event the Company receives FDA approval for the Maestro Rechargeable System.
	The Company has granted SVB a security interest in all of the Company’s assets, excluding intellectual property except with respect to all license, royalty fees and other revenues and income arising out of or relating to any of the intellectual property and all proceeds of the intellectual property. The Company also has entered into a negative pledge arrangement with SVB pursuant to which it has agreed not to encumber any of its intellectual property without SVB’s prior written consent.
	Pursuant to the Loan Agreement, on April 16, 2012, the Company issued SVB a warrant to purchase 106,746 shares of common stock, exercisable for ten years from the date of grant, at an exercise price of $2.34 per share.
	Scheduled debt principal payments are as follows as of September 30, 2013:
	Years ending December 31:
	Remaining three months in 2013	$	1,000,000
	2014		4,000,000
	2015		3,000,000
			8,000,000
	Less: Original issue discount		(171,591	)
	Notes payable, net	$	7,828,409

Stockbased_Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2013
Stock-based Compensation	'
	(6) Stock-based Compensation
	The fair value method of accounting for share-based payments is applied to all share-based payment awards issued to employees and where appropriate, nonemployees, unless another source of literature applies. When determining the measurement date of a nonemployee’s share-based payment award, the Company measures the stock options at fair value and remeasures such stock options to the current fair value until the performance date has been reached.
	Based on the application of these standards, stock-based compensation expense for stock-based awards under the Company’s Amended and Restated 2003 Stock Incentive Plan for the three and nine months ended September 30, 2013 and 2012 was allocated to operating expenses and employees and nonemployees as follows:
		Three months ended						Nine months ended
		September 30,						September 30,
		2013			2012			2013		2012
	Research and development	$	373,187		$	319,964		$	1,041,777	$	606,994
	Selling, general and administrative		1,157,186			1,008,747			3,335,178		2,132,325
	Total	$	1,530,373		$	1,328,711		$	4,376,955	$	2,739,319
		Three months ended						Nine months ended
		September 30,						September 30,
		2013			2012			2013		2012
	Employees	$	1,517,447		$	1,326,311		$	4,304,043	$	2,687,253
	Nonemployees		12,926			2,400			72,912		52,066
	Total	$	1,530,373		$	1,328,711		$	4,376,955	$	2,739,319
	As of September 30, 2013 there was approximately $15.4 million of total unrecognized compensation costs, net of estimated forfeitures, related to employee unvested stock option awards granted after January 1, 2006, which are expected to be recognized over a weighted-average period of 2.9 years.
	The estimated grant-date fair values of the stock options were calculated using the Black-Scholes valuation model, based on the following assumptions for the three and nine months ended September 30, 2013 and 2012:
		Employees		Employees
		Three months ended		Nine months ended September 30,
		September 30, 2012		2013	2012
	Risk-free interest rates	0.90%-0.97%		0.94%-1.33%	0.90%-1.09%
	Expected life	6.25 years		6.00-6.25 years	6.00-6.25 years
	Expected dividends	0%		0%	0%
	Expected volatility	137.58%-138.38%		148.00%-149.00%	123.18%-141.05%
	There were no new employee grants for the three months ended September 30, 2013.
		Nonemployees			Nonemployees
		Three months ended September 30,			Nine months ended September 30,
		2013		2012	2013		2012
	Risk-free interest rates	0.27%-0.92%		0.33%	0.27%-1.03%		0.24%-2.05%
	Expected life	1.76-3.67 years		2.76 years	1.76-3.92 years		2.00-9.25 years
	Expected dividends	0%		0%	0%		0%
	Expected volatility	90.00%-92.00%		80.13%	82.00%-125.00%		80.13%-139.80%
	Option activity under the Company’s Amended and Restated 2003 Stock Incentive Plan for the nine months ended September 30, 2013 was as follows:
					Outstanding Options
		Shares			Number of			Weighted-
		Available For			Shares			Average
		Grant						Exercise
								Price
	Balance, December 31, 2012		4,393,985			7,835,533		$	3.28
	Shares reserved		—			—			—
	Options granted		(4,256,000	)		4,256,000			1.33
	Options exercised		—			—			—
	Options cancelled		468,833			(468,833	)		3.06
	Balance, September 30, 2013		606,818			11,622,700			2.57

Stock_Sales

Stock Sales	9 Months Ended
	Sep. 30, 2013
Stock Sales	'
	(7) Stock Sales
	Equity Distribution Agreement—July 2013
	On July 31, 2013, the Company entered into an equity distribution agreement with Canaccord Genuity Inc. (Canaccord) to sell shares of the Company’s common stock having aggregate gross sales proceeds of up to $20.0 million, from time to time, through an “at-the-market” equity offering program (ATM) under which Canaccord will act as the Company’s sales agent. The Company will determine, at its sole discretion, the timing and number of shares to be sold under this ATM. The Company will pay Canaccord a commission for its services in acting as agent in the sale of common stock equal to 2.0% of the gross sales price per share of all shares sold through it as agent under the equity distribution agreement. As of September 30, 2013, the Company had sold 3,000,000 shares under the ATM at a weighted-average selling price of $1.18 per share for gross proceeds of approximately $3.6 million before deducting offering expenses. Subsequent to September 30, 2013 through November 8, 2013, the Company has sold an additional 2,175,000 shares under the ATM at a weighted-average selling price of $1.31 per share for gross proceeds of approximately $2.8 million before deducting offering expenses.
	Public Offering—February 2013
	On February 27, 2013, the Company closed a public offering, selling 13,770,000 shares of common stock, together with warrants to purchase approximately 5,508,000 shares of common stock at an aggregate price of $0.95 per share and corresponding warrant, for gross proceeds of $13.1 million before deducting offering expenses.
	The warrants have an exercise price of $1.14 per share of common stock and are exercisable for a period of five years from February 27, 2013. Holders of the warrants are not permitted to exercise those warrants for an amount of common stock that would result in the holder owning more than 19.99% of the Company’s common stock.
	Common Stock Purchase Agreement—October 2012
	On October 4, 2012, the Company entered into a Common Stock Purchase Agreement (the Purchase Agreement) with Terrapin Opportunity, L.P. (Terrapin) pursuant to which the Company could sell up to the lesser of $45.0 million of its common stock or 8,312,122 shares of its common stock over an approximately 24-month period pursuant to the terms of the Purchase Agreement. The Company was not obligated to utilize any portion of the facility and generally remained free to enter into and consummate other equity and debt financing transactions.
	On July 31, 2013, the Company terminated the Purchase Agreement with Terrapin. No shares of common stock were sold under the Purchase Agreement.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2013

Description of Business

'

Description of Business

EnteroMedics Inc. (formerly Beta Medical, Inc.) (the Company) is developing medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company was incorporated in the state of Minnesota on December 19, 2002 and was reincorporated in Delaware on July 22, 2004. The Company is in the development stage and since inception has devoted substantially all of its resources to recruiting personnel, developing its product technology, obtaining patents to protect its intellectual property and raising capital, and thus far has only derived revenues from its primary business activity in 2012. The Company is headquartered in St. Paul, Minnesota. In January 2006, the Company established EnteroMedics Europe Sárl, a wholly-owned subsidiary located in Switzerland.

Since inception, the Company has incurred losses through September 30, 2013 totaling $219.2 million and has not generated positive cash flows from operations. The Company expects such losses to continue into the foreseeable future as it continues to develop and commercialize its technologies. The Company may need to obtain additional financing and there can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. If adequate funds are not available, the Company may have to delay development or commercialization of products or license to third parties the rights to commercialize products or technologies that the Company would otherwise seek to commercialize. See Note 2.

Basis of Presentation

'

Basis of Presentation

The Company has prepared the accompanying condensed consolidated financial statements in conformity with accounting principles generally accepted in the United States of America. The Company’s fiscal year ends on December 31.

The accompanying condensed consolidated financial statements and notes thereto are unaudited. In the opinion of the Company’s management, these statements include all adjustments, which are of a normal recurring nature, necessary to present a fair presentation. Interim results are not necessarily indicative of results for a full year. The condensed consolidated balance sheet as of December 31, 2012 was derived from audited consolidated financial statements, but does not include all disclosures required by accounting principles generally accepted in the United States of America. The information included in this Form 10-Q should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

Use of Estimates

'

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Principles of Consolidation

'

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.

Fair Value of Financial Instruments

'

Fair Value of Financial Instruments

Carrying amounts of certain of the Company’s financial instruments, including cash and cash equivalents, restricted cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued liabilities approximate fair value due to their short maturities. The fair value of the Company’s long-term debt (including the current portion) is approximately $8.2 million as of September 30, 2013 based on the present value of estimated future cash flows using a discount rate commensurate with borrowing rates available to the Company. If measured at fair value in the condensed consolidated financial statements, long-term debt (including the current portion) would be classified as Level 2 in the fair value hierarchy.

The Company’s assets that are measured at fair value on a recurring basis are classified within Level 1 or Level 2 of the fair value hierarchy. The Company does not hold any assets that are measured at fair value using Level 3 inputs. The types of instruments the Company invests in that are valued based on quoted market prices in active markets include U.S. treasury securities. Such instruments are classified by the Company within Level 1 of the fair value hierarchy. U.S. treasuries are valued using unadjusted quoted prices for identical assets in active markets that the Company can access.

The types of instruments the Company invests in that are valued based on quoted prices in less active markets, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency include U.S. agency securities, commercial paper, U.S. corporate bonds and municipal obligations. Such instruments are classified by the Company within Level 2 of the fair value hierarchy. The Company values these types of assets using consensus pricing or a weighted average price, which is based on multiple pricing sources received from a variety of industry standard data providers (e.g. Bloomberg), security master files from large financial institutions, and other third-party sources. The multiple prices obtained are then used as inputs into a distribution-curve-based algorithm to determine the daily market price.

The Company did not hold any short-term investments as of September 30, 2013 and December 31, 2012.

Cash and Cash Equivalents

'

Cash and Cash Equivalents

The Company considers highly liquid investments generally with maturities of 90 days or less when purchased to be cash equivalents. Cash equivalents are stated at cost, which approximates market value. The Company’s cash equivalents are primarily in money market funds and certificates of deposit. The Company deposits its cash and cash equivalents in high-quality credit institutions. Under terms of the Company’s note payable agreement (see Note 5), in the event of default, the lender has the right to enforce an account control agreement and restrict the Company’s access to their cash and investment accounts.

Restricted Cash

'

Restricted Cash

The Company had $200,000 in a cash collateral money market account as of September 30, 2013 and December 31, 2012. Pursuant to a lease agreement the Company entered into with Roseville Properties Management Company in July 2008, the Company was required to deliver to Roseville Properties an irrevocable, unconditional, standby letter of credit in the amount of $200,000 on the second anniversary of the commencement of lease payments. The irrevocable standby letter of credit was issued by Silicon Valley Bank, who required the Company to set up a restricted cash collateral money market account to fully secure the standby letter of credit. The fully secured standby letter of credit was maintained through October 1, 2013, per the terms of the lease agreement.

Inventory

'

Inventory

The Company accounts for inventory at the lower of cost or market and records any long-term inventory as other assets in the condensed consolidated balance sheets.

Income Taxes

'

Income Taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carry-forwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance for deferred income tax assets is recorded when it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The Company has provided a full valuation allowance against the gross deferred tax assets. The Company’s policy is to classify interest and penalties related to income taxes as income tax expense in the condensed consolidated statements of operations.

Comprehensive Loss

'

Comprehensive Loss

Comprehensive loss is defined as the change in equity of a company during a period from transactions and other events and circumstances excluding transactions resulting from investment owners and distributions to owners. There was no difference from reported net loss for the three and nine months ended September 30, 2013. The difference from reported net loss for the three and nine months ended September 30, 2012 related entirely to changes in unrealized gains (losses) on available for sale investments.

Revenue Recognition

'

Revenue Recognition

The Company recognizes revenue when persuasive evidence of an arrangement exists, title or risk of loss has passed, the selling price is fixed or determinable and collection is reasonably assured. The Company sells products internationally through distributors and recognizes revenue upon sale to the distributor as these sales are considered to be final and no right of return or price protection exists. Terms of sales to international distributors are generally EXW, reflecting that goods are shipped “ex works,” in which risk of loss is assumed by the distributor at the shipping point. The Company does not provide for rights of return to customers on product sales and therefore does not record a provision for returns.

Research and Development Expenses

'

Research and Development Expenses

Research and development expenses are charged to expense as incurred. Research and development expenses include, but are not limited to, product development, clinical trial expenses, including supplies, devices, explants and revisions, regulatory expenses, payroll and other personnel expenses, materials and consulting costs.

Derivative Instruments

'

Derivative Instruments

The Company accounts for outstanding warrants that are not indexed to the Company’s stock or warrants issued when the Company has insufficient authorized and unissued stock available to share settle the outstanding warrants as derivative instruments, which require that the warrants be classified as a liability and measured at fair value with changes in fair value recognized currently in earnings and recorded separately in the condensed consolidated statements of operations.

Net Loss Per Share

'

Net Loss Per Share

Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is based on the weighted-average common shares outstanding during the period plus dilutive potential common shares calculated using the treasury stock method. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. The Company’s potential dilutive shares, which include outstanding common stock options and warrants, have not been included in the computation of diluted net loss per share for all periods as the result would be anti-dilutive.

The following table sets forth the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2013 and 2012:

Three months ended

Nine months ended

September 30,

September 30,

2013

2012

2013

2012

Numerator:

Net loss

$

(6,303,294

)

$

(5,846,840

)

$

(19,207,379

)

$

(16,433,386

)

Denominator for basic and diluted net loss per share:

Weighted-average common shares outstanding

55,978,107

40,984,216

52,864,039

38,810,762

Net loss per share—basic and diluted

$

(0.11

)

$

(0.14

)

$

(0.36

)

$

(0.42

)

The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:

September 30,

2013

2012

Stock options outstanding

11,622,700

7,879,730

Warrants to purchase common stock

25,565,950

21,493,883

Recently Issued Accounting Standards

'

Recently Issued Accounting Standards

There have been no significant changes in recent accounting pronouncements during the nine months ended September 30, 2013 as compared to the recent accounting pronouncements described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012.

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2013
Computation of Basic and Diluted Net Loss Per Share	'
	The following table sets forth the computation of basic and diluted net loss per share for the three and nine months ended September 30, 2013 and 2012:
		Three months ended						Nine months ended
		September 30,						September 30,
		2013			2012			2013			2012
	Numerator:
	Net loss	$	(6,303,294	)	$	(5,846,840	)	$	(19,207,379	)	$	(16,433,386	)
	Denominator for basic and diluted net loss per share:
	Weighted-average common shares outstanding		55,978,107			40,984,216			52,864,039			38,810,762
	Net loss per share—basic and diluted	$	(0.11	)	$	(0.14	)	$	(0.36	)	$	(0.42	)
Antidilutive Securities	'
	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share because to do so would be anti-dilutive as of the end of each period presented:
		September 30,
		2013			2012
	Stock options outstanding		11,622,700			7,879,730
	Warrants to purchase common stock		25,565,950			21,493,883

Inventory_Tables

Inventory (Tables)	9 Months Ended
	Sep. 30, 2013
Current Inventory	'
	Current inventory consists of the following as of:
		September 30,		December 31,
		2013		2012
	Raw materials	$	307,420	$	198,647
	Work-in-process		748,197		1,051,286
	Finished goods		116,658		21,274
	Inventory	$	1,172,275	$	1,271,207

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2013
Future Minimum Payments under Lease	'
	At September 30, 2013, future minimum payments under the lease are as follows:
	Years ending December 31:
	Remaining three months in 2013	$	72,480
	2014		291,369
	2015		221,789
		$	585,638

Notes_Payable_Tables

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2013
Debt Future Payments	'
	Scheduled debt principal payments are as follows as of September 30, 2013:
	Years ending December 31:
	Remaining three months in 2013	$	1,000,000
	2014		4,000,000
	2015		3,000,000
			8,000,000
	Less: Original issue discount		(171,591	)
	Notes payable, net	$	7,828,409

Stockbased_Compensation_Tables

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2013
Summary of Operating Expenses and Employee and Nonemployees	'
	Based on the application of these standards, stock-based compensation expense for stock-based awards under the Company’s Amended and Restated 2003 Stock Incentive Plan for the three and nine months ended September 30, 2013 and 2012 was allocated to operating expenses and employees and nonemployees as follows:
		Three months ended						Nine months ended
		September 30,						September 30,
		2013			2012			2013		2012
	Research and development	$	373,187		$	319,964		$	1,041,777	$	606,994
	Selling, general and administrative		1,157,186			1,008,747			3,335,178		2,132,325
	Total	$	1,530,373		$	1,328,711		$	4,376,955	$	2,739,319
		Three months ended						Nine months ended
		September 30,						September 30,
		2013			2012			2013		2012
	Employees	$	1,517,447		$	1,326,311		$	4,304,043	$	2,687,253
	Nonemployees		12,926			2,400			72,912		52,066
	Total	$	1,530,373		$	1,328,711		$	4,376,955	$	2,739,319
Stock Option Valuation Assumptions	'
	The estimated grant-date fair values of the stock options were calculated using the Black-Scholes valuation model, based on the following assumptions for the three and nine months ended September 30, 2013 and 2012:
		Employees		Employees
		Three months ended		Nine months ended September 30,
		September 30, 2012		2013	2012
	Risk-free interest rates	0.90%-0.97%		0.94%-1.33%	0.90%-1.09%
	Expected life	6.25 years		6.00-6.25 years	6.00-6.25 years
	Expected dividends	0%		0%	0%
	Expected volatility	137.58%-138.38%		148.00%-149.00%	123.18%-141.05%
	There were no new employee grants for the three months ended September 30, 2013.
		Nonemployees			Nonemployees
		Three months ended September 30,			Nine months ended September 30,
		2013		2012	2013		2012
	Risk-free interest rates	0.27%-0.92%		0.33%	0.27%-1.03%		0.24%-2.05%
	Expected life	1.76-3.67 years		2.76 years	1.76-3.92 years		2.00-9.25 years
	Expected dividends	0%		0%	0%		0%
	Expected volatility	90.00%-92.00%		80.13%	82.00%-125.00%		80.13%-139.80%
Summary of Stock Option Activity	'
	Option activity under the Company’s Amended and Restated 2003 Stock Incentive Plan for the nine months ended September 30, 2013 was as follows:
					Outstanding Options
		Shares			Number of			Weighted-
		Available For			Shares			Average
		Grant						Exercise
								Price
	Balance, December 31, 2012		4,393,985			7,835,533		$	3.28
	Shares reserved		—			—			—
	Options granted		(4,256,000	)		4,256,000			1.33
	Options exercised		—			—			—
	Options cancelled		468,833			(468,833	)		3.06
	Balance, September 30, 2013		606,818			11,622,700			2.57

Summary_of_Significant_Account3

Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		129 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Dec. 31, 2012
Schedule Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'
Net income (loss)	($6,303,294)	($5,846,840)	($19,207,379)	($16,433,386)	($219,248,823)	'
Long-term debt	8,200,000	'	8,200,000	'	8,200,000	'
Cash equivalents maturity period	'	'	'90 days	'	'	'
Cash collateral money market	200,000	'	200,000	'	200,000	200,000
Standby letter of credit amount	'	'	$200,000	'	'	'
Standby letters of credit	'	'	'	'	'	'
Schedule Of Significant Accounting Policies [Line Items]	'	'	'	'	'	'
Stand by letter of credit expiration date	'	'	1-Oct-13	'	'	'

Computation_of_Basic_and_Dilut

Computation of Basic and Diluted Net Loss Per Share (Detail) (USD $)	3 Months Ended		9 Months Ended		129 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Numerator:	'	'	'	'	'
Net loss	($6,303,294)	($5,846,840)	($19,207,379)	($16,433,386)	($219,248,823)
Denominator for basic and diluted net loss per share:	'	'	'	'	'
Weighted-average common shares outstanding	55,978,107	40,984,216	52,864,039	38,810,762	'
Net loss per share-basic and diluted	($0.11)	($0.14)	($0.36)	($0.42)	'

Potential_Shares_of_Common_Sto

Potential Shares of Common Stock Not Included in Calculation of Diluted Net Loss per Share (Detail)	9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012
Employee Stock Option	'	'
Anti-dilutive Securities	'	'
Anti-dilutive as of end of each period	11,622,700	7,879,730
Warrants to purchase common stock	'	'
Anti-dilutive Securities	'	'
Anti-dilutive as of end of each period	25,565,950	21,493,883

Liquidity_and_Management_Plans

Liquidity and Management Plans - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended		129 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
Liquidity and Managements Plans [Line Items]	'	'	'	'	'
Net income (loss)	($6,303,294)	($5,846,840)	($19,207,379)	($16,433,386)	($219,248,823)
Net cash used in operating activities	'	'	-14,112,690	-16,994,401	-183,775,216
Cash, cash equivalents and restricted cash	$21,300,000	'	$21,300,000	'	$21,300,000

Inventory_Additional_Informati

Inventory - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Inventory [Line Items]	'	'
Long-term inventory	$863,000	$862,000

Current_Inventory_Detail

Current Inventory (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Inventory [Line Items]	'	'
Raw materials	$307,420	$198,647
Work-in-process	748,197	1,051,286
Finished goods	116,658	21,274
Inventory	$1,172,275	$1,271,207

Commitments_and_Contingencies_1

Commitments and Contingencies - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Loss Contingencies [Line Items]	'	'	'	'
Operating lease agreement expiration date	'	'	30-Sep-15	'
Operating lease agreement rent expense	$67,718	$67,718	$203,154	$203,154
Number of months that require patients to be followed out in clinical trials	'	'	'60 months	'

Future_Minimum_Payments_Under_

Future Minimum Payments Under Lease (Detail) (USD $)	Sep. 30, 2013
Leases Future Minimum Payments [Line Items]	'
Remaining three months in 2013	$72,480
2014	291,369
2015	221,789
Total	$585,638

Notes_Payable_Additional_Infor

Notes Payable - Additional Information (Detail) (USD $)	9 Months Ended							1 Months Ended
	Sep. 30, 2013	Feb. 28, 2013	Apr. 23, 2012	Apr. 16, 2012	Apr. 23, 2012	Apr. 16, 2012	9-May-13	9-May-13	9-May-13	9-May-13	9-May-13
					Silicon Valley Bank	Silicon Valley Bank	15-Nov-13	15-Nov-13	15-Nov-13	15-Nov-13	15-Nov-13
					Installment		Silicon Valley Bank	Silicon Valley Bank	Silicon Valley Bank	Silicon Valley Bank	Silicon Valley Bank
									15-Apr-14	Until it receives FDA approval for the Maestro Rechargeable System	After FDA approval for the Maestro Rechargeable System
										BasisPoint	BasisPoint
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Term loans, agreed sum	'	'	'	'	'	$20,000,000	'	'	'	'	'
Principal amount of loan	'	'	10,000,000	10,000,000	'	'	'	'	'	'	'
Number of installments of repayment of debt	'	'	'	'	30	'	'	'	'	'	'
Repayment of principal amount	333,333	'	'	'	'	'	'	'	'	'	'
Loan agreement with fixed annual rate	'	'	8.00%	'	'	'	'	'	'	'	'
Final payment fee percentage	5.00%	'	'	'	'	'	'	'	'	'	'
Conditional amount to be placed in restricted account at SVB	7,500,000	'	'	'	'	'	'	'	'	'	'
Cumulative aggregate proceeds from new capital transactions	'	'	'	'	'	'	'	5,000,000	10,000,000	'	'
Liquidity ratio (unrestricted cash divided by outstanding debt)	'	'	'	'	'	'	'	'	'	1.25	0.75
Success fee percentage in the event the Company receives FDA approval for the Maestro Rechargeable System	'	'	'	'	'	'	$187,000	'	'	'	'
Issued warrant	'	'	'	'	'	106,746	'	'	'	'	'
Time for exercising warrant	'	'	'	'	'	'10 years	'	'	'	'	'
Warrant exercise price	'	1.14	'	'	'	2.34	'	'	'	'	'

Schedule_of_Debt_Principal_Pay

Schedule of Debt Principal Payments (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Debt Instrument [Line Items]	'	'
Remaining three months in 2013	$1,000,000	'
2014	4,000,000	'
2015	3,000,000	'
Notes payable, gross	8,000,000	'
Less: Original issue discount	-171,591	-316,028
Notes payable, net	$7,828,409	'

StockBased_Compensation_Expens

Stock-Based Compensation Expense for Stock-Based Awards (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Gross stock-based compensation expense	$1,530,373	$1,328,711	$4,376,955	$2,739,319
Research and development	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Gross stock-based compensation expense	373,187	319,964	1,041,777	606,994
Selling, general and administrative	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Gross stock-based compensation expense	1,157,186	1,008,747	3,335,178	2,132,325
Employees	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Gross stock-based compensation expense	1,517,447	1,326,311	4,304,043	2,687,253
Nonemployees	'	'	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'	'	'
Gross stock-based compensation expense	$12,926	$2,400	$72,912	$52,066

StockBased_Compensation_Additi

Stock-Based Compensation - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
In Millions, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Total unrecognized compensation costs related to non-vested stock options	$15.40	$15.40
Total unrecognized compensation costs related to non-vested stock options, weighted-average period of recognition	'	'2 years 10 months 24 days
New employee grants	0	'

Assumptions_for_Fair_Values_of

Assumptions for Fair Values of Stock Option (Detail)	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk-free interest rates, minimum	'	0.90%	0.94%	0.90%
Risk-free interest rates, maximum	'	0.97%	1.33%	1.09%
Expected life	'	'6 years 3 months	'	'
Expected dividends	'	0.00%	0.00%	0.00%
Expected volatility, minimum	'	137.58%	148.00%	123.18%
Expected volatility, maximum	'	138.38%	149.00%	141.05%
Minimum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expected life	'	'	'6 years	'6 years
Maximum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expected life	'	'	'6 years 3 months	'6 years 3 months
Non employees	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Risk-free interest rates	'	0.33%	'	'
Risk-free interest rates, minimum	0.27%	'	0.27%	0.24%
Risk-free interest rates, maximum	0.92%	'	1.03%	2.05%
Expected life	'	'2 years 9 months 4 days	'	'
Expected dividends	0.00%	0.00%	0.00%	0.00%
Expected volatility	'	80.13%	'	'
Expected volatility, minimum	90.00%	'	82.00%	80.13%
Expected volatility, maximum	92.00%	'	125.00%	139.80%
Non employees | Minimum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expected life	'1 year 9 months 4 days	'	'1 year 9 months 4 days	'2 years
Non employees | Maximum	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expected life	'3 years 8 months 1 day	'	'3 years 11 months 1 day	'9 years 3 months

Stock_Option_Activity_under_Am

Stock Option Activity under Amended and Restated Stock Incentive Plan (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013
Shares available for grant	'
Balance, December 31, 2012	4,393,985
Shares reserved	'
Options granted	-4,256,000
Options exercised	'
Options cancelled	468,833
Balance, September 30, 2013	606,818
Outstanding Options, number of shares	'
Balance, December 31, 2012	7,835,533
Shares reserved	'
Options granted	4,256,000
Options exercised	'
Options cancelled	-468,833
Balance, September 30, 2013	11,622,700
Outstanding Options, weighted-average exercise price	'
Balance, December 31, 2012	$3.28
Shares reserved	'
Options granted	$1.33
Options exercised	'
Options cancelled	$3.06
Balance, September 30, 2013	$2.57

Stock_Sales_Additional_Informa

Stock Sales - Additional Information (Detail) (USD $)	1 Months Ended		9 Months Ended		1 Months Ended
In Millions, except Share data, unless otherwise specified	Feb. 28, 2013	Oct. 31, 2012	Sep. 30, 2013	Jul. 31, 2013	Nov. 08, 2013	Jul. 31, 2013
					Subsequent Event	Maximum
Class of Stock [Line Items]	'	'	'	'	'	'
Gross proceeds before deducting estimate offering expenses	$13.10	'	$3.60	'	$2.80	$20
Commission or discount percentage on issue of shares	'	'	'	2.00%	'	'
Number of shares sold	'	'	3,000,000	'	2,175,000	'
Weighted average selling price of shares sold	'	'	$1.18	'	$1.31	'
Common stock shares issued, new issues	13,770,000	'	'	'	'	'
Warrants issued to purchase common stock	5,508,000	'	'	'	'	'
Aggregate share price	$0.95	'	'	'	'	'
Warrants, exercise price	1.14	'	'	'	'	'
Warrant, exercise period	'5 years	'	'	'	'	'
Maximum percentage of ownership restriction on warrant exercises	19.99%	'	'	'	'	'
Maximum Amount of common stock which can be sold under common stock purchase agreement	'	$45	'	'	'	'
Maximum Number of Shares of common stock which can be sold under common stock purchase agreement	'	8,312,122	'	'	'	'
Period for the sale of common stock	'	'24 months	'	'	'	'